Clinical Schizophrenia and Related Psychoses 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Aripiprazole induced myopia - case report and literature review: Aripiprazole induced myopia.
We report a case of myopia induced by aripiprazole.
METHODS: Case study and literature review on aripiprazole-induced myopia.
RESULTS: a 21-year-old male, with a first psychotic episode, developed myopia two weeks after initiating aripiprazole 20 mg/day. The symptoms of blurred vision were solved eight to ten days after switching to paliperidone. To date, seven cases of aripiprazole-induced myopia were reported in literature, all of them related to the oral formulation.
DISCUSSION: in the present case, as seen in seven previously reported cases, the patient presented with myopia after the initiation...
Source: Clinical Schizophrenia and Related Psychoses - January 5, 2019 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research
Clinical News.
Authors: Buckley PF
PMID: 30339051 [PubMed - in process] (Source: Clinical Schizophrenia and Related Psychoses)
Source: Clinical Schizophrenia and Related Psychoses - October 20, 2018 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research
Sustained-Release Risperidone via Subcutaneous Injection: A Systematic Review of RBP-7000 (PERSERIS ™) for the Treatment of Schizophrenia.
Sustained-Release Risperidone via Subcutaneous Injection: A Systematic Review of RBP-7000 (PERSERIS™) for the Treatment of Schizophrenia.
Clin Schizophr Relat Psychoses. 2018;12(3):130-141
Authors: Citrome L
Abstract
RBP-7000 (PERSERIS™) is a once-monthly subcutaneously administered formulation of risperidone that does not require oral supplementation when initiated. As with risperidone microspheres, RBP-7000 is required to be stored in a refrigerator. The injection kit, consisting of two syringes (one containing liquid polymer, the other containing risperidone powder), will n...
Source: Clinical Schizophrenia and Related Psychoses - October 20, 2018 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research
Myocarditis in a Patient on Clozapine: What did it?
Authors: Munjal S, Ferrando S
Abstract
We are presenting the case of a 37-year-old male with schizoaffective disorder who developed myocarditis within three weeks of starting on clozapine for his treatment-resistant psychosis. The patient also had a positive titer for Influenza A, which makes it a diagnostic dilemma regarding the cause of his myocarditis. It may be possible that the myocarditis was caused by the Influenza A virus or synergistically exacerbated the clozapine's propensity to cause it. Currently, there are no studies establishing the link between the two etiologies. As clozapine can be the on...
Source: Clinical Schizophrenia and Related Psychoses - July 25, 2018 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research
Among the Severely Mentally Ill, Who Responds to Ziprasidone?
This study examines some differences in response to ziprasidone, which has been shown to be effective, with a better metabolic side effect profile, but was little used in New York State Hospitals. The aim was to study state hospital patients switched to ziprasidone. The results led to questions about different responses in different groups. Subjects from state hospitals who needed a change of antipsychotic participated in this open-label, 8-week trial of up to 240-mg ziprasidone. Analyses included comparisons of the very different results from two sites. Of the 36 study subjects, 12 terminated early. The 17 outpatients fro...
Source: Clinical Schizophrenia and Related Psychoses - July 25, 2018 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research
Clinical News.
Authors: Buckley PF
PMID: 30040475 [PubMed - in process] (Source: Clinical Schizophrenia and Related Psychoses)
Source: Clinical Schizophrenia and Related Psychoses - July 25, 2018 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research
Aripiprazole Lauroxil NanoCrystal ® Dispersion Technology (Aristada Initio®).
Aripiprazole Lauroxil NanoCrystal® Dispersion Technology (Aristada Initio®).
Clin Schizophr Relat Psychoses. 2018;12(2):92-96
Authors: Ehret MJ, Davis E, Luttrell SE, Clark C
Abstract
Nonadherence to antipsychotic medications for the treatment of schizophrenia is a widely recognized concern, leading to poorer clinical outcomes and higher treatment costs. Long-acting injectable (LAI) antipsychotics offer an extended dosing interval option for patients, although the current options may require an oral overlap at initiation. Aripiprazole lauroxil is an LAI that offers multiple dosi...
Source: Clinical Schizophrenia and Related Psychoses - July 25, 2018 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research
Premenstrual Psychosis in an Adolescent: A Case Report.
We present an adolescent who suffered from a new episode of psychosis beginning just before the onset of menses. Her symptoms abated after the completion of menses and with the initiation of combined oral contraceptives and olanzapine.
PMID: 29944411 [PubMed - as supplied by publisher] (Source: Clinical Schizophrenia and Related Psychoses)
Source: Clinical Schizophrenia and Related Psychoses - June 28, 2018 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research
Methylphenidate as Treatment for Clozapine-Induced Sedation in Patients with Treatment-Resistant Schizophrenia.
CONCLUSION: Methylphenidate may be safe and effective in the management of clozapine-induced sedation in treatment-resistant schizophrenia. Large scale, placebo-controlled, double-blind trials are needed to further validate the safety and efficacy of methylphenidate as treatment for clozapine-induced sedation.
PMID: 29944412 [PubMed - as supplied by publisher] (Source: Clinical Schizophrenia and Related Psychoses)
Source: Clinical Schizophrenia and Related Psychoses - June 28, 2018 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research
Faux-Pas Test: A Proposal of a Standardized Short Version.
Authors: Fernández-Modamio M, Arrieta-Rodríguez M, Bengochea-Seco R, Santacoloma-Cabero I, Gómez de Tojeiro-Roce J, García-Polavieja B, González-Fraile E, Martín-Carrasco M, Griffin K, Gil-Sanz D
Abstract
Previous research on theory of mind suggests that people with schizophrenia have difficulties with complex mentalization tasks that involve the integration of cognition and affective mental states. One of the tools most commonly used to assess theory of mind is the Faux-Pas Test. However, it presents two main methodological problems: 1) the lack of a standard scoring system; 2) the different version...
Source: Clinical Schizophrenia and Related Psychoses - June 28, 2018 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research
An Exploratory Study of Exercise-related Effects on Memory and Hippocampal Connectivity in Schizophrenia.
Authors: Schwartz B, Teslovich T, You X, Cho J, Schooler N, Kokkinos P, Vaidya C
Abstract
Memory impairment in schizophrenia has been linked to abnormal functioning of fronto-temporal networks. In this pilot study, we investigated whether 12-weeks of exercise improved hippocampal-dependent memory functions and resting-state functional connectivity in middle-aged adults with schizophrenia. The exercise regimen was feasible, well-attended, and safe. There was a pre- to post-intervention increase in spatial memory accuracy that was correlated to an increase in hippocampal-prefrontal cortex connectivity. No in...
Source: Clinical Schizophrenia and Related Psychoses - June 28, 2018 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research
The use of long-acting antipsychotics for the management of aggressiveness in schizophrenia: a clinical overview.
THE USE OF LONG-ACTING ANTIPSYCHOTICS FOR THE MANAGEMENT OF AGGRESSIVENESS IN SCHIZOPHRENIA: A CLINICAL OVERVIEW.
Clin Schizophr Relat Psychoses. 2018 Jun 26;:
Authors: Buoli M, Rovera C, Esposito CM, Grassi S, Cahn W, Altamura AC
Abstract
Aggressive behaviour represents a challenge in the treatment of patients with schizophrenia, being often associated with clinical predictors of severity of illness such as poor insight, psychotic re-exacerbation, concomitant substance misuse or comorbidity with personality disorders. As psychotic relapses and consequent risk of aggressive behavi...
Source: Clinical Schizophrenia and Related Psychoses - June 28, 2018 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research
First-Episode Psychosis and Hypokalemia: A Case Report and Review of the Literature.
We present a case report of a young female who developed a first presentation of acute psychosis and in which complementary investigations revealed hypokalemia. The psychosis resolved in few hours after replacement therapy with potassium chloride. The patient returned her usual functioning after discharge and there were no signs of psychosis at six-month follow-up.
PMID: 29944416 [PubMed - as supplied by publisher] (Source: Clinical Schizophrenia and Related Psychoses)
Source: Clinical Schizophrenia and Related Psychoses - June 28, 2018 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research
Neurocryptococcosis in immunocompetent patient with psychosis.
CONCLUSIONS: We emphasize the importance of paying attention to subtle systemic and neurological signs and investigating the general medical condition cause in the case of a first psychotic episode.
PMID: 29944417 [PubMed - as supplied by publisher] (Source: Clinical Schizophrenia and Related Psychoses)
Source: Clinical Schizophrenia and Related Psychoses - June 28, 2018 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research
Re-titration rates after clozapine-induced neutropenia or agranulocytosis: A case report and literature review.
Authors: Boazak M, Kahn B, Cox L, Ragazino J, Goldsmith DR, Cotes RO
Abstract
Clozapine-induced neutropenia occurs in 3-5% of individuals treated with clozapine. Current US guidelines require interruption of clozapine when the absolute neutrophil count (ANC) drops below 1000 cells/mm3. There is minimal available guidance for what dosing schedule to use when restarting clozapine after an episode of neutropenia. Here, we present a case of a 50-year-old Caucasian female with a history of schizoaffective disorder who was successfully rechallenged on clozapine one month after developing clozapine-induced neutro...
Source: Clinical Schizophrenia and Related Psychoses - June 28, 2018 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research
